| 选择性PPARγ调节剂治疗糖尿病的研究新进展 |
| |
| 引用本文： | 环奕,申竹芳. 选择性PPARγ调节剂治疗糖尿病的研究新进展[J]. 中国药理学通报, 2008, 24(2): 149-152 |
| |
| 作者姓名： | 环奕 申竹芳 |
| |
| 作者单位： | 中国医学科学院·北京协和医学院药物研究所,北京,100050 |
| |
| 基金项目： | 国家自然科学基金 , 北京市自然科学基金 |
| |
| 摘 要： | 过氧化物酶体增殖物激活受体γ是一类主要调控糖脂代谢与脂肪细胞分化的核受体,与肥胖、胰岛素抵抗和糖尿病的发生发展密切相关,其激动剂作为胰岛素增敏剂治疗2型糖尿病也被临床广泛应用。近年来,随着对PPARγ信号通路和胰岛素增敏剂的深入研究,使我们对选择性PPARγ调节剂类胰岛素增敏剂的认识不断完善和更新。该文主要阐述选择性PPARγ调节剂类胰岛素增敏剂的作用机制和药物研究的最新进展。
|
| 关 键 词： | 选择性PPARγ调节剂 过氧化物酶体增殖物激活受体γ 胰岛素增敏剂 糖尿病 |
| 文章编号： | 1001-1978（2008）02-0149-04 |
| 收稿时间： | 2007-10-25 |
| 修稿时间： | 2007-12-18 |
The update research on selective PPARγ modulator in anti-diabetic treatment |
| |
| HUAN Yi,SHEN Zhu-fang. The update research on selective PPARγ modulator in anti-diabetic treatment[J]. Chinese Pharmacological Bulletin, 2008, 24(2): 149-152 |
| |
| Authors: | HUAN Yi SHEN Zhu-fang |
| |
| Abstract: | PPARγ is a kind of nuclear receptors responsible for the regulation of glucose and lipid metabolisim and adipocyte difference,which is related with the pathogenesis of obesity,insulin resistance and type 2 diabetes mellitus.PPARγ agonists as insulin sensitizer have been used in the clinical treatment for type 2 diabetes for more than decades.Recently,with the further research plunging into the PPAR signaling pathway and insulin sensitizer,the recognition of this crucial nuclear receptor has been renewed and developed.The aim of this review is to report the update research outcomes. |
| |
| Keywords: | selective PPARγ modulator peroxisome proliferators activated receptor γ insulin sensitizer diabetes |
| 本文献已被 万方数据 等数据库收录！ |
|
